NanoBio Corporation Successfully Completes Phase 2b Study in Herpes Labialis

Ann Arbor, Mich., March 17, 2008 – NanoBio Corporation reported top-level findings today from its phase 2b study of NB-001, a topical lotion to treat herpes labialis (cold sores). The randomized, double-blind, vehicle-controlled study met its primary and secondary endpoints by demonstrating clear efficacy and safety in 482 patients.

NanoBio’s uniquely formulated lotion resulted in faster healing of cold sores, at a rate never seen before by

Continue reading: NanoBio Successfully Completes Phase 2b Study in Herpes Labialis